Jpmorgan Chase & CO Belite Bio, Inc Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Belite Bio, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 658 shares of BLTE stock, worth $29,939. This represents 0.0% of its overall portfolio holdings.
Number of Shares
658
Previous 14,267
95.39%
Holding current value
$29,939
Previous $652,000
96.17%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BLTE
# of Institutions
12Shares Held
58.3KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA16.7KShares$758,4850.0% of portfolio
-
Marshall Wace, LLP London, X010.6KShares$481,5720.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.7KShares$395,8500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$304,8500.0% of portfolio
-
Morgan Stanley New York, NY6.09KShares$277,0950.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.13B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...